Previously recorded as Fibrogen, Inc. (to 2026)
19 patents currently held
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jan 2027. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
5
Ending by 2030
Jan 2027
Next term end
10
Patent families
When these terms end
Held patents by the year their term ends
notable patents
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Feb 2032 · High confidence
Also notable
Ends Jan 2027 · Medium confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Mar 2033 · High confidence
Also notable
Ends Jun 2028 · High confidence
Also notable
Ends Jul 2033 · High confidence
Also notable
Ends Feb 2027 · Medium confidence
Also notable
Ends Jun 2034 · High confidence
Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase
US 8,921,389
Cited by 57 later US patents, top 10% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof
US 7,863,292
Cited by 48 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Crystalline Forms of a Prolyl Hydroxylase Inhibitor
US 9,115,085
Cited by 24 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
4 -Hydroxy- Isoquinoline Compounds as Hif Hydroxylase Inhibitors
US 9,409,892
Cited by 14 later US patents, top 25% of utility patents granted in 2016 in our data, and renewed at every maintenance window due so far. Protection runs to 2033.
Cyanoisoquinoline Compounds and Methods of Use Thereof
US 7,928,120
Cited by 60 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2028.
Process for Making Isoquinoline Compounds
US 9,708,269
Granted 2017 and renewed at every maintenance window due so far. Protection runs to 2033. A terminal disclaimer caps this term to an earlier patent's.
Methods for Improving Kidney Function
US 8,318,703
Renewed at every maintenance window since the 2012 grant; no more fees are due before its term ends in 2027.
Pharmaceutical Formulations of a Hif Hydroxylase Inhibitor
US 10,765,672
Granted 2020. Computed term ends 2034.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 25, 2027The maintenance fee for Crystalline Forms of a Prolyl Hydroxylase Inhibitor (US 9,115,085) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 1 fee due Sep 1, 2027The maintenance fee for Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase (US 9,271,970) comes due Sep 1, 2027. Unpaid by Mar 1, 2028, it lapses early.
- 1 fee due Nov 17, 2027The maintenance fee for Process for Making Isoquinoline Compounds (US 9,340,511) comes due Nov 17, 2027. Unpaid by May 17, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 10 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Crystalline Forms of a Prolyl Hydroxylase Inhibitor | 7 in force | to Jul 2033 |
| Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase | 3 in force | to Feb 2032 |
| Process for Making Isoquinoline Compounds | 2 in force | to Jul 2033 |
| Pharmaceutical Formulations of a Hif Hydroxylase Inhibitor | 1 in force | to Jun 2034 |
| 4 -Hydroxy- Isoquinoline Compounds as Hif Hydroxylase Inhibitors | 1 in force | to Mar 2033 |
| Methods for Improving Kidney Function | 1 in force | to Feb 2027 |
| Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof | 1 in force | to Jan 2027 |
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,863,292 | Novel Nitrogen-Containing Heteroaryl Compounds and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,318,703 | Methods for Improving Kidney Function In force · Medium confidence | In force | Medium confidence | |
| US 7,696,223 | Pyrrolo- and Thiazolo-Pyridine Compounds, and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 7,928,120 | Cyanoisoquinoline Compounds and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,088,381 | Methods of Treatment of Cardiovascular Disease Using Anti-Ctgf Agents In force · High confidence | In force | High confidence | |
| US 8,921,389 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence | In force | High confidence | |
| US 9,271,970 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence | In force | High confidence | |
| US 9,695,170 | Naphthyridine Derivatives as Inhibitors of Hypoxia Inducible Factor (HIF) Hydroxylase In force · High confidence | In force | High confidence | |
| US 9,409,892 | 4 -Hydroxy- Isoquinoline Compounds as Hif Hydroxylase Inhibitors In force · High confidence | In force | High confidence | |
| US 8,883,823 | Crystalline Forms of a Prolyl Hydroxylase Inhibitor In force · High confidence | In force | High confidence |
Also on record, not counted in the 19: 5 patents ended · 1 application pending. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.